跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 7,001 条关于
“MRT-51443”
全部
7,001
临床试验
6,163
药物
428
机构
29
资讯
381
去年
Monte Rosa Presents Promising Preclinical Data for CDK2 Molecular Glue Degrader in HR-Positive Breast Cancer at AACR 2025
9个月前
Monte Rosa Therapeutics Reports Promising MRT-8102 Cardiovascular Data and Prepares Updated MRT-2359 Cancer Results
8个月前
Monte Rosa's MRT-8102 Demonstrates 85% Reduction in Cardiovascular Inflammation Marker in Phase 1 Trial
去年
Monte Rosa and Novartis Partner to Advance VAV1 Molecular Glue Degrader MRT-6160
去年
Monte Rosa Therapeutics Receives FDA Clearance for MRT-8102, First NEK7-Targeted Molecular Glue Degrader for Inflammatory Diseases
9天前
Novartis Doses First Patient in Phase 2 Sjögren's Trial of VAV1 Degrader MRT-6160, Triggering $50M Payment to Monte Rosa
去年
Novartis and Monte Rosa Therapeutics Partner to Advance VAV1 Degrader for Immune-Mediated Conditions
去年
Monte Rosa Therapeutics Announces Key Milestones for Molecular Glue Degraders in 2025
去年
Novartis Licenses Monte Rosa's Molecular Glue Degrader for Autoimmune Diseases
去年
Novartis and Monte Rosa Therapeutics Partner to Advance VAV1 Molecular Glue Degrader
第 1 页,共 39 页
上一页
下一页